AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01690832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard saline infusion
Description: i.v. 1 ml/kg/h saline infusion from 6 hours before the procedure to 12 hours after the procedure
Study NCT01690832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fenoldopam infusion
Description: combination of i.v. 1 ml/kg/h saline infusion and fenoldopam administration (0.08 mcg/Kg/min) from 6 hours before the procedure to 12 hours after the procedure
Study NCT03373812 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blepharoptosis repair
Description: levator advancement or mullerectomy
Study NCT00148590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Daily dose of 20 mg Memantine add-on to Risperidone vs Placebo add-on to Risperidone
Study NCT00148590 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily dose of 20 mg Memantine add-on to Risperidone vs Placebo add-on to Risperidone
Study NCT02633111 — intervention group
Intervention type: OTHER
Intervention: collected at pre-treatment tumor biopsy
Description: to identify the tumor-specific clonotype
Study NCT02633111 — intervention group
Intervention type: OTHER
Intervention: Peripheral blood tests
Description: for MRD analysis at 3, 6, 9, 12, 15, 18, 21, and at relapse (+/- 1 month).
Study NCT00854854 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TKCell
Description: TKCell 150ml IV for 7times after each FOLFOX-4 regimen :~From the second cycle of FOLFOX4(start Day1),TKCell is administered in Day3 and Day8.In the third cycle of FOLFOX4(Day1),TKCell is administered in Day3 and Day8.In the fourth cycle of FOLFOX4(Day1),TKCell is administered in Day8.In the fifth cycle of FOLFOX4(Day1),TKCell is administered in Day8.In the sixth cycle of FOLFOX4(Day1),TKCell is administered in Day8
Study NCT01400633 — intervention group
Intervention type: DRUG
Intervention: decitabine injection
Description: decitabine intravenous injection 20mg/m2 once a day for 5 consecutive days every 4 weeks
Study NCT01153256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: magnesium sulphate
Description: The patients of group M receive 50 mg/kg of magnesium sulphate in 100 ml of isotonic saline over 10 min immediately before anaesthesia induction. After induction of anesthesia with alfentanil (10 μg/kg) and propofol (2 mg/kg), rocuronium 0.6 mg/kg is given over 5 s in a running infusion.
Study NCT01153256 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Patients in the group R-0.6 receive the same volume of isotonic saline over the same period, and rocuronium 0.6 mg/kg is given after the induction of anesthesia with alfentanil (10 μg/kg) and propofol (2 mg/kg).
Study NCT01153256 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Patients in the group R-0.6 receive the same volume of isotonic saline over the same period, and rocuronium 0.9 mg/kg is given after the induction of anesthesia with alfentanil (10 μg/kg) and propofol (2 mg/kg).
Study NCT00675545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, Carboplatin
Description: Docetaxel Form: A white, lyophilized powder in vials of 50, 150, and 450 mg each, which should be stored at room temperature in a light-protected area.~Carboplatin Form: Taxotere is supplied as a sterile, non-aqueous, viscous solution with an accompanying sterile diluent (13% ethanol in water for injection). 20 and 80 mg strengths are available.
Study NCT03232138 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sulforaphane
Description: Sulforaphane (SF) is a naturally occurring substance (phytochemical) found in cruciferous vegetables.
Study NCT03232138 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive ingredients
Study NCT04610151 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: guided imagery
Description: Guided Imagery CD: A guided imagery CD was prepared by a web designer with the recommendations of the researcher to include relaxing, soft and slow-paced, mixed nature sounds and photographs towards reducing pain in lower extremity surgical operation patients. The directives used for guidance, the audio recordings created as a result of literature review and the video lasted for 13 minutes (
Study NCT02669108 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PET/ MRI of the Testis
Description: PET/MRI of the testis will be performed upon the patient achieving azoospermia (following the vasectomy), or 25 ejaculations and following proven azoospermia (via standard of care semen analysis).
Study NCT01653847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus with MMF
Description: Standard dose Tacrolimus and MMF. This will follow standard of care procedures at Northwestern Memorial Hospital's Comprehensive Transplant Center. MMF trough or area under the concentration time curve (AUC) shall not be used to adjust dosing. In this group, Tacrolimus will be initiated according to our practice. The Tacrolimus dose will be adjusted from day 3 on to achieve a target whole blood trough concentration of 8 ng/mL to 10 ng/mL. From month 2 until Month 6, the target Tacrolimus trough level will be reduced to 6 ng/mL to 8 ng/mL. After month 6, the target level of Tacrolimus will be reduced to 4 ng/mL to 8 ng/mL.
Study NCT01653847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group 2: Tacrolimus with Everolimus.
Description: From day 5 on, the starting dose of Everolimus (0.75 mg bid) will be increased if the trough level is \< 3 ng/mL, or reduced if the trough level is > 8 ng/mL. Tacrolimus will be initiated according to our practice. In this treatment arm, the Tacrolimus dose will be adjusted from day 3 on, to a target whole blood trough concentration of 4 ng/mL to 7 ng/mL. From month 2 until Month 6, the target Tacrolimus trough level will be 3 ng/mL to 6 ng/mL. After month 6, the Tacrolimus dose should be adjusted in order to achieve a target trough level of 2 ng/mL to 5 ng/mL. MMF dose will be initiated as 1 g b.i.d. (2 g/day). Adjustments should be made for adverse events including but not limited to gastrointestinal intolerance and a decrease in white blood cell (WBC).
Study NCT00512044 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local anesthesia (pudendal block)
Description: local anesthesia as indicated
Study NCT04015882 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise therapy
Description: The exercise therapy group will make by physiotherapist supervision.
Study NCT02444143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus extended release
Study NCT02444143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus extended release
Study NCT04777188 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Intramyocardial Septal Radiofrequency Ablation for hypertrophic obstructive cardiomyopathy
Description: Under transthoracic echocardiography (TTE) guidance, the puncture site is positioned at the apex. A guiding line is applied along the septal long axis and the radiofrequency ablation electrode needle(17G, Cool-tip™ RF Ablation System and Switching Controller;Medtronic, Minneapolis, MN, USA) pierced towards the hypertrophic anterior interventricular septum (AIVS) 8-10 mm from the subaortic valve. Each ablation lasts for up to 12 min and the ablation power is gradually increased from 30-40W. Then, the ablation needle is withdrawn 10 mm to prepare for the next application. Overall, 3-4 applications are performed in each patient. The ablation creates an area of thermal coagulative myocardial necrosis that appears as a hyperechogenic reflection detected by TTE. If deemed necessary, we repeat the procedure at the posterior interventricular septum (PIVS).
Study NCT00512044 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: general anesthesia (spinal and general)
Description: general according to guidelines
Study NCT03922971 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Option 1: National comparison
Description: Ability to view center's rate compared with all others.
Study NCT03922971 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Option 2: National comparison with benchmarking
Description: Ability to view center's rate compared with the others with a similar patient comorbidity profile and in addition to viewing option 1.
Study NCT04697992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin c 20%
Description: one eye was treated with vitamin c 20% + microneedling a session was done every 2 weeks a total of 4 sessions (other eye was placebo treated with saline + microneedling).
Study NCT04697992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid 5mg/ml
Description: one eye was treated with tranexamin acid 5 mg/ml + microneedling a session was done every 2 weeks a total of 4 sessions (other eye was placebo treated with saline + microneedling)
Study NCT04728464 — intervention group
Intervention type: PROCEDURE
Intervention: Periodontally Accelerated Osteogenic Orthodontics (PAOO)
Description: Fixed appliance will be placed for every patient, then surgical procedure will be applied after reflecting a full-thickness labial flap.
Study NCT03899103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: First course Course Rituximab at Randomization.
Study NCT03899103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: First course Course Rituximab at Randomization.
Study NCT03899103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Addition of Maintenance Mycophenolate Mofetil from 4 Month onwards
Study NCT03656549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed + oral folinic acid rescue
Description: 3+3 dose escalation study of pemetrexed in patients with impaired renal function in combination with roal folinic acid rescue
Study NCT02707159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel / gemcitabine
Description: Patients will receive gemcitabine/nab-paclitaxel combination chemotherapy
Study NCT01171833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: 2.0 vol% prefilled in a corrugated circuit.
Study NCT01171833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: 6.0 vol% prefilled in a corrugated circuit.
Study NCT01171833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoflurane
Description: 1.2 vol% prefilled in a corrugated circuit.
Study NCT02592811 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP
Description: Common bile duct cannulation with a cannulation catheter
Study NCT02284919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]ISO-1
Description: \[18F\]ISO-1 PET/CT scan
Study NCT01593111 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Environmental Intervention
Description: Home-based environmental intervention
Study NCT04213339 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kegel Exercises
Description: Kegel exercise group will get exercise within duration of 3 to 6 weeks based on age factor. Kegel exercise can be performed at any time and at any place without any restrictions.~following steps will be followed by kegel exercises group members:~1. Tighten and hold pelvic floor muscles for five seconds (count 1 one thousand, 2 one thousand, 3 one thousand, 4 one thousand, 5 one thousand).~2. Relax pelvic muscles and perform 10 to 20 Kegel exercises three to four times each day.~3. Squeeze the muscles in anus like holding a bowel movement focus penile area~4. Relax the pelvic floor muscles after each attempt.~5. Repeat this exercise 10 to 20 times.~6. While performing Kegel exercises:~Do not hold the breath. Do not push down. Squeeze the muscles together tightly and imagine, trying to lift this muscle up. Do not tighten the muscles in the stomach, buttocks, or thighs.~While the control group did not participate in any kegel exercises
Study NCT04002830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elelyso
Description: Taliglucerase alfa is currently an approved therapy in the United States and many other countries for adults and children with a confirmed diagnosis of Type 1 GD ,and is also approved for use in Type 3 GD in a small number of countries.
Study NCT01544621 — intervention group
Intervention type: OTHER
Intervention: Smoking cessation
Description: Smoking cessation
Study NCT00686335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lodotra
Description: Administered with food at approximately 10 pm during the 4 week treatment period; patients received the identical dose of Lodotra as received of IR prednisone during the run-in period.
Study NCT00686335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cortancyl
Description: Administered in the morning with food during the 4 week run-in period; patients remained on their respective pre-study dose of prednisone or equivalent standardized to 5 mg and 1 mg tablets of immediate release (IR) prednisone (Cortancyl).
Study NCT02907554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine A
Description: the intervention group receives 2.5 mg/kg of cyclosporine
Study NCT02907554 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: control group receives a placebo
Study NCT03008122 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT03008122 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zika Virus Purified Inactivated Vaccine (ZPIV)
Description: Zika Virus Purified Inactivated Vaccine with aluminum hydroxide adjuvant.
Study NCT03997162 — intervention group
Intervention type: OTHER
Intervention: Best Practice
Description: Complete standard of care enhanced recovery after surgery protocol
Study NCT03997162 — intervention group
Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03997162 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03981536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP-101
Description: Administered by intravenous infusion (IV)
Study NCT00992160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW597599
Description: GW597599 15mg tablet
Study NCT00992160 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match GW597599 15mg tablet
Study NCT03257995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol maleate
Description: 150 μg via Concept1 device
Study NCT02592811 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Sphincterotomy
Description: Endoscopic large sphincterotomy
Study NCT02592811 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Large Balloon Dilatation of Oddi Sphincter
Description: Large Balloon Dilatation : with the HERCULES, Cook 12, 15, 18 or 20 mm of diameter (adapted to stone diameter)
Study NCT02592811 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stone extraction
Description: After dilatation, extraction of stones is done with dormia basket or extraction balloon and if not possible a mechanical lithotripsy is performed
Study NCT03046914 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: HLA-B*5801 test
Description: Check whether a participant has HLA-B\*5801 allele or not, before administration of allopurinol
Study NCT00719433 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: robot therapy (ARMin)
Description: therapy of the affected arm with a robot for eight weeks, three times weekly for one hour
Study NCT00719433 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: physical and occupational therapy of the affected arm for eight weeks, three times weekly for one hour
Study NCT03559426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antipsychotic Reduction
Description: Antipsychotic medication is gradually reduced and discontinued if possible. A flexible individualised antipsychotic reduction schedule is devised for each patient by the research team, based on the participant's initial antipsychotic regime. Antipsychotic dose is reduced incrementally every two months, with flexibility to speed up or slow down the schedule in discussion with the patient. The antipsychotic reduction extends over a period of between six to 12 months, although this may be extended according to individual circumstances.
Study NCT03559426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antipsychotic Maintenance
Description: Participants continue to receive antipsychotic treatment at the original dose for the 24 month duration of the trial. Increases or minor adjustments to antipsychotic medication are permitted.
Study NCT03754192 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: perfusion Computed Tomography
Description: Will be carried before liver surgery
Study NCT02145611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glibenclamide
Description: Glibenclamide
Study NCT02145611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vildagliptin
Description: Vildagliptin
Study NCT03257995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol acetate
Description: 150 μg via Concept1 device
Study NCT03257995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsule containing no active ingredients delivered via Concept1 device
Study NCT02633111 — intervention group
Intervention type: DEVICE
Intervention: PET/CT
Description: at 3, 6, 9, 15, 18, 21 and at relapse(+/- 1 month)
Study NCT00892268 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture therapy
Description: Undergo acupuncture
Study NCT00892268 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pain therapy
Description: Receive standard care
Study NCT03678441 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BrainCheck Cognitive Assessment
Description: Receive BrainCheck cognitive assessment
Study NCT03678441 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BrainCheck Cognitive Assessment
Description: Receive BrainCheck cognitive assessment
Study NCT03678441 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cognitive Assessment
Description: Receive pen and paper cognitive assessment
Study NCT03678441 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Assessment
Description: Receive pen and paper cognitive assessment
Study NCT05008042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mecobalamin 5 MG
Description: The Active substance of vitamin B12 is Mecobalamin 5 mg/ml is given intramuscularly
Study NCT05008042 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator : NaCl 9 mg/ml
Description: Sodium Chloride (NaCL) 9 mg / ml 2 ml, isotonic solution for parenteral use (Baxter) is given intramuscularly.
Study NCT03815656 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STN alone
Description: DBS stimulation of STN alone
Study NCT03815656 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GPi alone
Description: DBS stimulation of GPi alone
Study NCT03815656 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STN + GPi
Description: cooperative DBS stimulation of STN and GPi sites
Study NCT03815656 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop stimulation
Description: adaptive DBS stimulation of STN and/or GPi sites
Study NCT04623502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 13C-Glucose
Description: Patients in the 13C-glucose arm will receive an infusion of a 13C-glucose solution. In most cases, the glucose infusion will be administered for 2-3 hours prior to resection of the mass. During the surgical procedure, 2-4mL of blood will be obtained approximately every 30 minutes to monitor blood glucose and/or blood pH. The infusion will be stopped after resection.
Study NCT04623502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 13C-Acetate
Description: Patients in the 13C-acetate arm will receive an infusion of a 13C-acetate solution. In most cases, the acetate infusion will be administered for 2-3 hours prior to resection of the mass. During the surgical procedure, 2-4mL of blood will be obtained approximately every 30 minutes to monitor blood glucose and/or blood pH. The infusion will be stopped after resection.
Study NCT04623502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 13C-Lactate
Description: Patients in the 13C-lactate arm will receive an infusion of a 13C-lactate solution. In most cases, the lactate infusion will be administered for 2-3 hours prior to resection of the mass. During the surgical procedure, 2-4mL of blood will be obtained approximately every 30 minutes to monitor blood glucose and/or blood pH. The infusion will be stopped after resection.
Study NCT04623502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 13C-Glutamine
Description: Patients in the 13C-glutamine arm will receive an infusion of a 13C-glutamine solution. In most cases, the glutamine infusion will be administered for 2-3 hours prior to resection of the mass. During the surgical procedure, 2-4mL of blood will be obtained approximately every 30 minutes to monitor blood glucose and/or blood pH. The infusion will be stopped after resection.